(Q38474278)
Statements
1 reference
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies (English)
1 reference
Randy D Gascoyne
1 reference
Laurie H Sehn
1 reference
Sarit E Assouline
1 reference
Douglas A Stewart
1 reference
Joy Mangel
1 reference
Gregg Fine
1 reference
Susan Frances-Lasserre
1 reference
David J Carlile
1 reference
Michael Crump
1 reference
20 March 2012
1 reference
1 reference
119
1 reference
22
1 reference
5118-5125
1 reference
Identifiers
1 reference
1 reference